Rapid alteration of serum interleukin-6 levels may predict the reactivity of i.v. cyclophosphamide pulse therapy in systemic sclerosis-associated interstitial lung disease

Hiroko Numajiri, Ayumi Yoshizaki, Takemichi Fukasawa, Satoshi Ebata, Kouki Nakamura, Takashi Yamashita, Ryosuke Saigusa, Syunsuke Miura, Megumi Hirabayashi, Asako Yoshizaki, Hayakazu Sumida, Yoshihide Asano, Yutaka Kazoe, Kazuma Mawatari, Takehiko Kitamori, Shinichi Sato

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Systemic sclerosis (SSc) is an autoimmune disorder characterized by excessive extracellular matrix deposition. Although SSc-associated interstitial lung disease (ILD) is one of the most important complications as a cause of death in SSc, prediction factors of treatment reactivity in SSc-ILD are still unclear. To assess relationships between interleukin (IL)-6 and reactivity to treatment, we measured serum IL-6 levels in 23 of active SSc-ILD patients under i.v. cyclophosphamide (IVCY) therapy and 20 of stabilized SSc-ILD, using the high-sensitivity enzyme-linked immunoassay system. Serum IL-6 levels in active SSc-ILD patients were significantly higher than those in stabilized SSc-ILD patients. Among active SSc-ILD patients, baseline serum IL-6 levels were not significantly different between IVCY responders and non-responders. Meanwhile, serum IL-6 levels after three IVCY doses out of a total of six were decreased in responders but not in non-responders. Regarding changes of parameters by the three doses of a total of six of IVCY, change in serum IL-6 levels correlated inversely with that in values of pulmonary function test. Thus, the rapid decrease in serum IL-6 levels during a couple of doses may predict the efficacy of IVCY therapy against SSc-ILD.

Original languageEnglish
Pages (from-to)1221-1224
Number of pages4
JournalJournal of Dermatology
Volume45
Issue number10
DOIs
Publication statusPublished - 2018 Oct 1

Fingerprint

Systemic Scleroderma
Interstitial Lung Diseases
Cyclophosphamide
Interleukin-6
Serum
Therapeutics
Respiratory Function Tests
Immunoenzyme Techniques
Extracellular Matrix
Cause of Death

Keywords

  • i.v. cyclophosphamide
  • interleukin-6
  • micro-enzyme-linked immunoassay
  • predictive factor
  • systemic sclerosis interstitial lung disease

ASJC Scopus subject areas

  • Dermatology

Cite this

Rapid alteration of serum interleukin-6 levels may predict the reactivity of i.v. cyclophosphamide pulse therapy in systemic sclerosis-associated interstitial lung disease. / Numajiri, Hiroko; Yoshizaki, Ayumi; Fukasawa, Takemichi; Ebata, Satoshi; Nakamura, Kouki; Yamashita, Takashi; Saigusa, Ryosuke; Miura, Syunsuke; Hirabayashi, Megumi; Yoshizaki, Asako; Sumida, Hayakazu; Asano, Yoshihide; Kazoe, Yutaka; Mawatari, Kazuma; Kitamori, Takehiko; Sato, Shinichi.

In: Journal of Dermatology, Vol. 45, No. 10, 01.10.2018, p. 1221-1224.

Research output: Contribution to journalArticle

Numajiri, H, Yoshizaki, A, Fukasawa, T, Ebata, S, Nakamura, K, Yamashita, T, Saigusa, R, Miura, S, Hirabayashi, M, Yoshizaki, A, Sumida, H, Asano, Y, Kazoe, Y, Mawatari, K, Kitamori, T & Sato, S 2018, 'Rapid alteration of serum interleukin-6 levels may predict the reactivity of i.v. cyclophosphamide pulse therapy in systemic sclerosis-associated interstitial lung disease', Journal of Dermatology, vol. 45, no. 10, pp. 1221-1224. https://doi.org/10.1111/1346-8138.14580
Numajiri, Hiroko ; Yoshizaki, Ayumi ; Fukasawa, Takemichi ; Ebata, Satoshi ; Nakamura, Kouki ; Yamashita, Takashi ; Saigusa, Ryosuke ; Miura, Syunsuke ; Hirabayashi, Megumi ; Yoshizaki, Asako ; Sumida, Hayakazu ; Asano, Yoshihide ; Kazoe, Yutaka ; Mawatari, Kazuma ; Kitamori, Takehiko ; Sato, Shinichi. / Rapid alteration of serum interleukin-6 levels may predict the reactivity of i.v. cyclophosphamide pulse therapy in systemic sclerosis-associated interstitial lung disease. In: Journal of Dermatology. 2018 ; Vol. 45, No. 10. pp. 1221-1224.
@article{516e787c9527470ea7ab553ba6910bd8,
title = "Rapid alteration of serum interleukin-6 levels may predict the reactivity of i.v. cyclophosphamide pulse therapy in systemic sclerosis-associated interstitial lung disease",
abstract = "Systemic sclerosis (SSc) is an autoimmune disorder characterized by excessive extracellular matrix deposition. Although SSc-associated interstitial lung disease (ILD) is one of the most important complications as a cause of death in SSc, prediction factors of treatment reactivity in SSc-ILD are still unclear. To assess relationships between interleukin (IL)-6 and reactivity to treatment, we measured serum IL-6 levels in 23 of active SSc-ILD patients under i.v. cyclophosphamide (IVCY) therapy and 20 of stabilized SSc-ILD, using the high-sensitivity enzyme-linked immunoassay system. Serum IL-6 levels in active SSc-ILD patients were significantly higher than those in stabilized SSc-ILD patients. Among active SSc-ILD patients, baseline serum IL-6 levels were not significantly different between IVCY responders and non-responders. Meanwhile, serum IL-6 levels after three IVCY doses out of a total of six were decreased in responders but not in non-responders. Regarding changes of parameters by the three doses of a total of six of IVCY, change in serum IL-6 levels correlated inversely with that in values of pulmonary function test. Thus, the rapid decrease in serum IL-6 levels during a couple of doses may predict the efficacy of IVCY therapy against SSc-ILD.",
keywords = "i.v. cyclophosphamide, interleukin-6, micro-enzyme-linked immunoassay, predictive factor, systemic sclerosis interstitial lung disease",
author = "Hiroko Numajiri and Ayumi Yoshizaki and Takemichi Fukasawa and Satoshi Ebata and Kouki Nakamura and Takashi Yamashita and Ryosuke Saigusa and Syunsuke Miura and Megumi Hirabayashi and Asako Yoshizaki and Hayakazu Sumida and Yoshihide Asano and Yutaka Kazoe and Kazuma Mawatari and Takehiko Kitamori and Shinichi Sato",
year = "2018",
month = "10",
day = "1",
doi = "10.1111/1346-8138.14580",
language = "English",
volume = "45",
pages = "1221--1224",
journal = "Journal of Dermatology",
issn = "0385-2407",
publisher = "Wiley-Blackwell",
number = "10",

}

TY - JOUR

T1 - Rapid alteration of serum interleukin-6 levels may predict the reactivity of i.v. cyclophosphamide pulse therapy in systemic sclerosis-associated interstitial lung disease

AU - Numajiri, Hiroko

AU - Yoshizaki, Ayumi

AU - Fukasawa, Takemichi

AU - Ebata, Satoshi

AU - Nakamura, Kouki

AU - Yamashita, Takashi

AU - Saigusa, Ryosuke

AU - Miura, Syunsuke

AU - Hirabayashi, Megumi

AU - Yoshizaki, Asako

AU - Sumida, Hayakazu

AU - Asano, Yoshihide

AU - Kazoe, Yutaka

AU - Mawatari, Kazuma

AU - Kitamori, Takehiko

AU - Sato, Shinichi

PY - 2018/10/1

Y1 - 2018/10/1

N2 - Systemic sclerosis (SSc) is an autoimmune disorder characterized by excessive extracellular matrix deposition. Although SSc-associated interstitial lung disease (ILD) is one of the most important complications as a cause of death in SSc, prediction factors of treatment reactivity in SSc-ILD are still unclear. To assess relationships between interleukin (IL)-6 and reactivity to treatment, we measured serum IL-6 levels in 23 of active SSc-ILD patients under i.v. cyclophosphamide (IVCY) therapy and 20 of stabilized SSc-ILD, using the high-sensitivity enzyme-linked immunoassay system. Serum IL-6 levels in active SSc-ILD patients were significantly higher than those in stabilized SSc-ILD patients. Among active SSc-ILD patients, baseline serum IL-6 levels were not significantly different between IVCY responders and non-responders. Meanwhile, serum IL-6 levels after three IVCY doses out of a total of six were decreased in responders but not in non-responders. Regarding changes of parameters by the three doses of a total of six of IVCY, change in serum IL-6 levels correlated inversely with that in values of pulmonary function test. Thus, the rapid decrease in serum IL-6 levels during a couple of doses may predict the efficacy of IVCY therapy against SSc-ILD.

AB - Systemic sclerosis (SSc) is an autoimmune disorder characterized by excessive extracellular matrix deposition. Although SSc-associated interstitial lung disease (ILD) is one of the most important complications as a cause of death in SSc, prediction factors of treatment reactivity in SSc-ILD are still unclear. To assess relationships between interleukin (IL)-6 and reactivity to treatment, we measured serum IL-6 levels in 23 of active SSc-ILD patients under i.v. cyclophosphamide (IVCY) therapy and 20 of stabilized SSc-ILD, using the high-sensitivity enzyme-linked immunoassay system. Serum IL-6 levels in active SSc-ILD patients were significantly higher than those in stabilized SSc-ILD patients. Among active SSc-ILD patients, baseline serum IL-6 levels were not significantly different between IVCY responders and non-responders. Meanwhile, serum IL-6 levels after three IVCY doses out of a total of six were decreased in responders but not in non-responders. Regarding changes of parameters by the three doses of a total of six of IVCY, change in serum IL-6 levels correlated inversely with that in values of pulmonary function test. Thus, the rapid decrease in serum IL-6 levels during a couple of doses may predict the efficacy of IVCY therapy against SSc-ILD.

KW - i.v. cyclophosphamide

KW - interleukin-6

KW - micro-enzyme-linked immunoassay

KW - predictive factor

KW - systemic sclerosis interstitial lung disease

UR - http://www.scopus.com/inward/record.url?scp=85051171247&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85051171247&partnerID=8YFLogxK

U2 - 10.1111/1346-8138.14580

DO - 10.1111/1346-8138.14580

M3 - Article

C2 - 30051925

AN - SCOPUS:85051171247

VL - 45

SP - 1221

EP - 1224

JO - Journal of Dermatology

JF - Journal of Dermatology

SN - 0385-2407

IS - 10

ER -